Trinity Biotech (TRIB) has released an update.
Trinity Biotech has acquired Metabolomics Diagnostics, an Irish deep-tech company known for its preeclampsia risk prediction test, PrePsia, which is expected to launch in the U.S. in 2025 through Trinity’s Immco reference lab. This strategic acquisition enhances Trinity’s diagnostics platform with advanced machine learning and bioinformatics for maternal health, aiming to address the urgent clinical needs in this sector. The transaction, valued at around $1.3 million, is anticipated to be accretive to Trinity’s growth and capabilities.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
